Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia  by Hoogewerf, M. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01535.x
Prognostic factors for early clinical failure in patients with severe
community-acquired pneumonia
M. Hoogewerf1, J. J. Oosterheert1, E. Hak2, I. M. Hoepelman1,3 and M. J. M. Bonten1,2,3
1Department of Internal Medicine and Infectious Diseases, 2Julius Center for Health Sciences and
Primary Care, 3Eijkman Winkler Institute for Microbiology, Infectious Diseases and Inﬂammation,
University Medical Center Utrecht, The Netherlands
ABSTRACT
For patients with community-acquired pneumonia (CAP), clinical response during the ﬁrst days of
treatment is predictive of clinical outcome. As risk assessments can improve the efﬁciency of pneumonia
management, a prospective cohort study to assess clinical, biochemical and microbiological predictors of
early clinical failure was conducted in patients with severe CAP (pneumonia severity index score of >90
or according to the American Thoracic Society deﬁnition). Failure was assessed at day 3 and was deﬁned
as death, a need for mechanical ventilation, respiratory rate >25 ⁄min, PaO2 <55 mm Hg, oxygen
saturation <90%, haemodynamic instability, temperature >38C or confusion. Of 260 patients, 80 (31%)
had early clinical failure, associated mainly with a respiratory rate >25 ⁄minute (n = 34), oxygen satura-
tion <90% (n = 28) and confusion (n = 20). In multivariate logistic regression analysis, failure was
associated independently with altered mental state (OR 3.19, 95% CI 1.75–5.80), arterial PaH <7.35 mm
Hg (OR 4.29, 95% CI 1.53–12.05) and PaO2 <60 mm Hg (OR 1.75, 95% CI 0.97–3.15). A history of heart
failure was associated inversely with clinical failure (OR 0.30, 95% CI 0.10–0.96). Patients who failed to
respond had a higher 28-day mortality rate and a longer hospital stay. It was concluded that routine
clinical and biochemical information can be used to predict early clinical failure in patients with severe
CAP.
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INTRODUCTION
Community-acquired pneumonia (CAP) is a com-
mon disease that is associated with serious com-
plications such as respiratory insufﬁciency, sepsis
and death. CAP requires hospitalisation of 15–
50% of patients, and 5–10% of patients require
management in an intensive care unit (ICU) [1–7].
Despite advances in antimicrobial therapy, the
mortality rate among hospitalised patients is still
high, ranging from 2% to 30% [8]. Clinical
response during the ﬁrst 2–3 days of treatment
appears to predict outcome [9–11]. Non-response
is associated with increased morbidity and mor-
tality, but once clinical stability has been
achieved, clinical deterioration caused by pneu-
monia is rare [12]. Risk assessments could help
physicians to improve the efﬁciency of pneu-
monia treatment, with optimal monitoring of
high-risk patients preventing unnecessary com-
plications, ICU admissions or deaths; patients at
low risk for treatment failure may be switched
from parenteral to oral antibiotics early in the
treatment process, thereby potentially reducing
the length of hospital stay and leading to more
efﬁcient use of available healthcare resources.
There is currently an absence of data to predict
the response (or failure to respond) to therapy
of patients treated for severe CAP. Recent studies
have analysed risk-factors for early clinical failure
in patient cohorts with mild-to-severe CAP, and
found that independent factors associated with
early clinical failure were multilobar pneumonia,
pleural effusion, a pneumonia severity index (PSI)
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score >90, Legionella pneumonia, Gram-negative
pneumonia, liver disease, leukopenia, dyspnoea
and confusion [13–15]. Current criteria, such as
the APACHE II and PSI scores, only predict
mortality, and do not seem to be sufﬁciently
accurate to guide clinical care. Moreover, these
algorithms include >15 variables and are imprac-
tical to use routinely [16–20]. Therefore, the aim of
the present study was to assess clinical, biochemi-
cal and microbiological predictors of early clinical
failure in patients hospitalised with severe CAP.
PATIENTS AND METHODS
Patients and setting
This study analysed patients included in a multicentre,
prospective randomised trial of the cost-effectiveness of an
early switch from parenteral to oral therapy for severe CAP.
The study was performed in two university medical centres
and ﬁve teaching hospitals in The Netherlands between July
2000 and June 2003. The study was approved by the medical
ethics committees of all participating hospitals, and all patients
gave written informed consent to participate. Adult patients
(aged ‡18 years) admitted with severe CAP were eligible for
inclusion in the study. Pneumonia was deﬁned as a new or
progressive inﬁltrate on chest X-ray, plus at least two of the
following criteria: cough; sputum production; rectal tempera-
ture >38C or <36.1C; auscultatory ﬁndings consistent with
pneumonia; leukocytosis (> 10 000 ⁄mm3, or >15% bands); C-
reactive protein more than three-fold the normal upper limit;
and positive blood culture or positive culture of pleural ﬂuid
[21]. Severe pneumonia was deﬁned as PSI >90 (Fine class IV
or V) or as fulﬁlling the American Thoracic Society criteria for
severe CAP [22]. Patients who had been treated for this
episode of pneumonia with antibiotics in the outpatient setting
were also included. Patients with cystic ﬁbrosis, known
colonisation with Gram-negative bacteria following structural
damage to the respiratory tract, a life-expectancy of <1 month
because of underlying disease, infections other than pneumo-
nia requiring antibiotic treatment, or immunosuppression
(neutropenia <0.5 · 109 ⁄L or a CD4 count <200 ⁄mm3), and
patients admitted directly to an ICU, were excluded. Criteria
for ICU admission included respiratory failure or haemody-
namic instability not responding to adequate intravenous ﬂuid
therapy and requiring vasopressor support. All patients
received intravenous treatment with antimicrobial agents for
at least 3 days.
Microbial analysis
Sputum and blood samples were collected, cultured and
evaluated according to standard procedures. Microorganisms
cultured from blood or sputum were recorded. In addition,
NOW tests (Binax Inc., Portland, ME, USA) were used to detect
urinary antigen for Legionella pneumophila and Streptococcus
pneumoniae. Acute and convalescent sera were collected and
tested for Mycoplasma pneumoniae, L. pneumophila and Chlamy-
dia pneumoniae. Any non-contaminating microorganism cul-
tured from a blood or sputum sample, or detected by urinary
antigen testing, was considered to be a cause for the episode of
pneumonia. For M. pneumoniae, a four-fold or greater increase
in titre between paired sera, or a single titre of ‡1:40, in
immune ﬂuorescence tests (Serodia-MycoII; Fujirebio Inc.,
Malvern, PA, USA), was considered to be indicative of
infection [23]. For L. pneumophila, a four-fold increase in the
antibody titre to ‡1:128, or single titres of ‡1:256, were con-
sidered to be suggestive of Legionella pneumonia [24]. For C.
pneumoniae, detection of IgM above established values, sero-
conversion of IgG between acute and convalescence samples,
high amounts of IgG in single titres, or a combination of these
factors, were considered to be serological evidence of infection
(ELISA; Savyon Diagnostics Ltd, Ashdod, Israel).
Deﬁnitions
Early clinical failure was assessed after 3 days and was
deﬁned as death, a need for mechanical ventilation, respiratory
rate >25 ⁄min, oxygen saturation <90%, Pa02 <55 mm Hg,
haemodynamic instability, altered mental state, or fever (<1C
decline in temperature if >38.5C on admission) [25]. A
changed mental state was deﬁned as an acute alteration in
the mental state of the patient, as observed by family or the
treating physician. If none of these features was present,
patients were considered to be responders. Inappropriate
therapy was deﬁned as treatment with antibiotics to which the
pathogens identiﬁed were not susceptible, e.g., b-lactam
monotherapy for atypical pathogens such as C. pneumoniae,
M. pneumoniae and L. pneumophila.
Clinical characteristics and course
A clinical history was taken upon admission and a physical
examination was performed. Demographical criteria and the
medical history were recorded. Neoplastic disease was deﬁned
as any cancer, except basal or squamous cell cancer of the skin,
that was active at the time of presentation or had been
diagnosed during the previous year [16]. PSI and APACHE II
were scored, arterial blood gas analysis on room air was
measured, routine chemical and haematological laboratory
tests were performed, and a chest X-ray was taken [16,18].
Antibiotic treatment instituted by the treating physician was
recorded. Antibiotic prescriptions were based on the Dutch
guidelines for CAP management and were not dictated by the
study protocol, except with regard to a switch to oral treatment
on the third day following admission [26]. Response to
treatment was evaluated by the principal investigator and
dedicated research nurses on the third day of hospitalisation.
Early failure was assessed using vital parameters, arterial
blood gas analysis on room air, routine laboratory tests and
physical examination. In-hospital clinical data, such as tem-
perature, blood pressure, O2 saturation on room air, heart rate
and respiratory rate, were measured daily. All patients were
followed for a maximum of 28 days.
Statistical analysis
To identify individual risk-factors for early clinical failure,
descriptive statistics were calculated as proportions and means
(SD) to describe baseline characteristics in the two outcome
groups (early response and early failure), using SPSS for
Windows, v.11.5 (SPSS Inc., Chicago, IL, USA). The construc-
tion of the prognostic model began with univariate assessment
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of the association of each characteristic and early failure by
estimation of OR and the corresponding 95% CIs for the total
study population. In the next stage, multivariate logistic
regression modelling was applied to select those variables that
were associated with early failure, with p <0.10 as criterion for
entry [27]. Forward selection was also performed to verify
whether any previously deleted potentially relevant character-
istic had been eliminated incorrectly from the model. For each
patient, the individual probability of the outcome was calcula-
ted from the ﬁnal model (predicted probability) [28].
Model evaluation
The reliability of the multivariate logistic regression model
was determined by the Hosmer-Lemeshow goodness-of-ﬁt
statistic [27]. The area under the receiver operator curve (ROC)
was used to assess the model’s discriminative ability [28,29].
The area under the ROC represents the probability that the
logistic regression model will assign a higher probability of the
outcome to a randomly chosen patient with an outcome than
to a randomly chosen patient without an outcome. An area
under the curve (AUC) estimate of 0.5 indicates no discrim-
ination, whereas an estimate of 1.0 indicates perfect discrim-
ination. Models with AUC values between 0.70 and 0.79 are
generally considered as having moderate discriminative prop-
erties, and those ‡0.80 as good.
Development and applicability of the prediction rule
The regression coefﬁcients of the derived multivariate model
were used to construct the prediction rule. The presence or
absence of speciﬁc characteristics was coded as 1 (present) or 0
(absent). To simplify interpretation, the coefﬁcients of the ﬁnal
model were ﬁrst divided by the lowest coefﬁcient and the
regression coefﬁcients were rounded to develop an overall
score value in the ﬁnal prognostic scores. The scores for
individual prognostic variables were added to form the
prognostic score for clinical failure.
RESULTS
Between July 2000 and June 2003, 273 consecutive
patients with severe CAP were included in the
study.Thirteenpatientswere subsequently exclud-
ed from analysis: six patients withdrew
informed consent; six patients had other infec-
tions outside the respiratory tract that required
antibiotic treatment; and data concerning early
failure were incomplete for one patient. Of the 260
remaining patients, 180 (69%) were responders
and 80 (31%) had early clinical failure. Reasons
for failure are shown in Table 1. A single failure
criterion at day 3 was present in 46 (57%)
patients, while multiple failure criteria were
present in 34 (43%) patients.
In univariate analysis, total PSI score, APACHE
II score, lower Glasgow Coma Score, presence of a
changed mental state, arterial pH <7.35 and
arterial PaO2 <60 mm Hg (variables of the PSI
score) were signiﬁcantly more predictive of early
failure. A history of chronic heart failure was
found more often among early responders
(Table 2). Causative microorganisms were identi-
ﬁed in 134 (52%) patients, in 90 (50%) responders
and in 45 (56%) patients with early failure
(Table 3). The most frequently isolated microor-
ganism in both groups was S. pneumoniae. Gram-
negative microorganisms were identiﬁed more
often among inpatients with early failure (OR
2.21, 95% CI 1.04–4.69). The initial therapy insti-
tuted most frequently was b-lactam monotherapy
(Table 4). Initial therapy with macrolide ⁄ b-lactam
combinations was associated with early clinical
failure in univariate analysis.
In multivariate analysis, the simplest predictive
model with the highest predictive value inclu-
ded altered mental state, arterial PaH <7.35,
PaO2 <60 mm Hg and an absence of a history of
Table 1. Reasons for early clinical failure
Reasons for failure
(evaluated at third day of hospitalisation)
Failure
n = 80 (31%)
Death 5 (6%)
Need for mechanical ventilation 5 (6%)
Respiratory rate >25 ⁄min 34 (42%)
Oxygen saturation <90% 28 (35%)
Fever 19 (24%)
Altered mental state 20 (25%)
Haemodynamically unstable 4 (5%)
Multiple features 34 (43%)





n = 80 OR 95% CI p
Age 67.9 (16.0%) 69.15 (16.8%) 1.01 1.00–1.02 0.57
Pneumonia severity
index score
108.3 (23.9%) 123.9 (26.2%) 1.03 1.01–1.04 <0.001
APACHE score 13.3 (4.4%) 14.8 (5.1%) 1.07 1.01–1.13 0.03
Glasgow coma score 14.7 (1.1%) 14.4 (1.1%) 0.80 0.62–1.02 0.07
Female gender 57 (32%) 23 (29%) 0.87 0.49–1.55 0.69
Nursing home 5 (3%) 4 (5%) 1.80 0.48–7.05 0.37
Mental state change 39 (22%) 36 (45%) 2.96 1.68–5.21 <0.001
Pleural effusion X-ray 30 (17%) 17 (21%) 1.03 0.96–1.10 0.38
Temperature <35C
or >40C
24 (13%) 11 (14%) 1.00 0.95–1.06 0.93
Systolic BP <90 mm Hg 4 (2%) 3 (4%) 1.03 0.95–1.11 0.48
Heart rate >125 ⁄min 39 (22%) 21 (26%) 1.03 0.97–1.09 0.41
Respiratory rate >30 ⁄min 55 (31%) 31 (39%) 1.03 0.99–1.05 0.20
Arterial PaH <7.35 mm Hg 7 (4%) 12 (15%) 4.36 1.65–11.55 0.003
Arterial Pa02 <60 mm Hg 56 (31%) 35 (44%) 1.72 1.00–2.96 0.05
PaO2 66.9 (19.5%) 69.3 (27.9%) 1.01 0.99–1.02 0.43
pH 7.45 (0.06%) 7.43 (0.08%) 0.03 0.00–0.18 0.006
Systolic blood pressure 134.3 (24.5%) 138.5 (30.8%) 1.01 1.00–1.02 0.24
Temperature 38.6 (1.2%) 38.3 (1.2%) 0.85 0.68–1.06 0.15
Respiratory rate 26.3 (8.1%) 28.1 (9.8%) 1.02 0.99–1.06 0.16
Heart rate 105.5 (22.0%) 106.7 (24.5%) 1.00 0.99–1.01 0.71
Medical history
Chronic heart failure 27 (15%) 4 (5%) 0.30 0.10–0.88 0.03
Neoplasm 44 (24%) 18 (23%) 1.00 0.98–1.02 0.73
Cerebrovascular incident 13 (7%) 7 (9%) 1.02 0.93–1.12 0.67
Kidney disease 17 (9%) 6 (8%) 0.98 0.89–1.08 0.61
Hoogewerf et al. Prognostic factors for community-acquired pneumonia 1099
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 1097–1104
heart failure as independent predictors of early
clinical failure (area under the ROC curve 0.70,
95% CI 0.63–0.77; Table 5). As the results of
microbiological investigations of sputum are not
available upon admission, those results were not
included in the analysis.
From the multivariate model, a prediction rule
was derived in which a score was assigned to the
presence of each variable. The predicted probab-
ility of outcome was determined as 1 ⁄ (1 + e-LP),
where the linear predictor (LP) = )1.41 + (1.16
altered mental status) + (1.46 · pH <7.35) +
()1.19 · heart failure) + (0.56 · arterial PaO2 <60
mm Hg). A prognostic score for each patient
(minimum )2 to maximum 6 points), reﬂecting
the probability of early failure, was calculated by
adding the scores of relevant characteristics.
Patients with a cut-off of <1 point had an 18%
possibility of early clinical failure, whereas
patients with a cut-off point of >3 points had a
75% possibility of failure (Table 6).
Inappropriate therapy
Ten (22%) patients with early clinical failure and
18 (20%) patients who responded to treatment
received inappropriate therapy, based on the
results of microbiological culture (OR 1.43, 95%
CI 0.60–3.40). All patients who received inappro-
priate therapy remained alive at day 28 (Table 7).
Of ten patients who experienced early failure and
received inappropriate therapy, four had Gram-
negative bacteria (two Pseudomonas aeruginosa and
two Enterobacter cloacae) isolated from sputum
samples, in one case in combination with S.
pneumoniae. The other six patients had serological
evidence of infection with an atypical pathogen,
including two cases with S. pneumoniae isolated
from sputum samples (one in combination with
pneumococcal bacteraemia). In all patients,
empirical therapy was appropriate for S. pneumo-
niae as a probable cause of CAP.
Of 18 patients who responded and received
inappropriate therapy, three had Gram-negative
bacteria (P. aeruginosa, E. cloacae and Acinetobacter
spp.) isolated from sputum samples, in one case
in combination with S. pneumoniae. One patient
had a blood culture positive for Citrobacter freun-
dii, with no other cause for CAP identiﬁed, but
responded clinically after receiving amoxycillin at
day 3. Another patient had Aspergillus isolated
from sputum samples (together with S. pneumo-
niae), but had no apparent risk-factors for yeast
infection. One patient had a positive urinary
antigen test for L. pneumophila, and had S. pneu-
moniae isolated from tracheal aspirates. This
patient showed a rapid clinical response with
penicillin therapy. The remaining 12 patients had
serological evidence of infection with an atypical






n = 80 OR 95% CI p
Streptococcus pneumoniae 49 (27%) 20 (25%) 0.89 0.49–1.63 0.71
Haemophilus inﬂuenzae 11 (6%) 3 (4%) 0.60 0.16–2.21 0.44
Other Gram-negative bacteria 17 (9%) 15 (19%) 2.21 1.04–4.69 0.04
Escherichia coli 3 6
Enterobacter spp. 2 2
Klebsiella spp. 5 1
Pseudomonas spp. 0 2
Othera 7 4
Chlamydia pneumoniae 10 (6%) 8 (10%) 1.89 0.72–4.98 0.20
Legionella pneumophila 7 (4%) 3 (4%) 0.96 0.24–3.82 0.96
Mycoplasma pneumoniae 4 (2%) 4 (5%) 2.32 0.56–9.50 0.24
Multiple pathogens 20 (11%) 9 (11%) 1.01 0.44–2.34 0.97
Other pathogensb 12 (7%) 5 (6%) 0.88 0.32–2.44 0.81
Unknown aetiology 90 (50%) 35 (44%) 0.85 0.49–1.50 0.56
aMoraxella catarrhalis, Citrobacter freundii, Proteus mirabilis, Acinetobacter spp.
bStaphylococcus aureus, Aspergillus spp.






n = 80 OR 95% CI p
b-lactam monotherapy 109 (61%) 44 (55%) 0.80 0.47–1.36 0.40
Macrolide monotherapy 3 (1%) 1 (1%) 0.75 0.08–7.29 0.80
Cephalosporin monotherapy 33 (18%) 13 (16%) 0.86 0.43–1.75 0.69
Other monotherapya 14 (8%) 3 (4%) 0.46 0.13–1.66 0.24
b-lactam ⁄macrolide combination 12 (7%) 12 (15%) 2.47 1.06–5.77 0.04
Cephalosporin ⁄macrolide
combination
6 (3%) 5 (6%) 1.93 0.57–6.53 0.29
Macrolide ⁄ other combination 3 (2%) 2 (3%) 1.51 0.25–9.23 0.65
Inappropriate treatmentb 18 (20%) 10 (22%) 1.43 0.60–3.40 0.42
aFluoroquinolones (ciproﬂoxacin), tetracyclines (doxycycline), penicillins, co-trim-
oxazole.
bA microorganism was detected in 135 patients.
Table 5. Results of multivariate analysis
Characteristic Exp(B) 95%CI p
Altered mental status 3.19 1.75–5.80 <0.001
Arterial PaH 4.29 1.53–12.05 0.006
Heart failure 0.30 0.10–0.96 0.04
Arterial PaO2 1.75 0.97–3.15 0.063
Table 6. Cut-off points of prediction rule for early failure
in patients hospitalised with community-acquired pneu-
monia
Points scorea Responders (%) Failures (%) Total (patients)
)2–0 82 18 121
1–3 60 40 131
4–6 25 75 8
aScores: altered mental status, 2 points; pH <7.35, 3 points; PaO2 <60, 1 point; heart
failure, )2 points; maximum score 6 points.
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pathogen, but all showed a good clinical response
with b-lactam therapy at day 3. None of the
patients receiving inappropriate therapy had been
switched to appropriate therapy at day 3.
Mortality
During the follow-up period of 28 days (inpa-
tients and outpatients), patients with early clinical
failure had a signiﬁcantly higher chance of all-
cause death and had longer lengths of hospital
stay. Nine (12%) patients with early clinical
failure died, not including the ﬁve patients who
died before day 3, whereas eight (4.4%) patients
who responded early died (OR 2.93, 95% CI 1.09–
7.92). The length of hospital stay of patients with
early clinical failure was 13.4 ± 5.3 days, com-
pared with 9.6 ± 4.7 days for early responders
(mean difference 3.8 days, 95% CI 2.6–5.4 days).
DISCUSSION
Clinical and biochemical data that are assessed
routinely for patients with CAP can be used to
determine the likelihood of early clinical failure in
patients hospitalised with severe CAP. Early
clinical failure is associated with increased mor-
tality and a longer stay in hospital. Close monit-
oring of patients at high risk for treatment failure
may prevent unnecessary deaths, ICU admissions
and associated costs.
The strengths of the present study were the
prospectively collected data, strict criteria for
inclusion, and the focus on patients with a high
risk for early clinical failure. In addition, early
failure was evaluated according to previously
deﬁned and generally accepted criteria. Until
now, no studies have analysed prognostic fac-
tors for early clinical failure in patients with
severe CAP. Arterial PaH <7.35 mm Hg, arterial
Pa02 <60 mm Hg, altered mental state upon
admission, and an absence of a history of
chronic heart failure, were independent predic-
tors of early clinical failure in patients treated
for severe CAP. Isolation of Gram-negative
pathogens was also a strong predictor for early
clinical failure, but as culture results from
sputum are not available at the time of admis-












clinical failure at day 3
Mortality
at day 28
1 Yes Pseudomonas aeruginosa Sputum Amoxycillin Fever No
2 Yes Chlamydia pneumoniae Serology Amoxycillin Fever No
3 Yes C. pneumoniae Serology Amoxycillin Fever No
4 Yes C. pneumoniae ⁄
Mycoplasma pneumoniae
Serology Escherichia coli ⁄
Streptococcus pneumoniae (sputum)
Ceftriaxone Respiratory rate > 25 ⁄min No
5 Yes Enterobacter cloacae Sputum Amoxycillin Oxygen saturation < 90% +
respiratory rate > 25 ⁄min
No
6 Yes E. cloacae Sputum Amoxycillin Respiratory rate > 25 ⁄min No
7 Yes C. pneumoniae Serology S. pneumoniae
(blood culture + sputum)
Amoxycillin Oxygen saturation < 90% No
8 Yes P. aeruginosa Sputum S. pneumoniae (sputum) Amoxycillin Oxygen saturation < 90% + PaO2 < 55 No
9 Yes M. pneumoniae Serology Amoxycillin Fever No
10 Yes M. pneumoniae Serology Ceftriaxone Oxygen saturation < 90% + PaO2 < 55 No
11 No Legionella pneumophila ⁄
C. pneumoniae
Serology Amoxycillin No
12 No C. pneumoniae ⁄
M. pneumoniae
Serology Amoxycillin No
13 No E. cloacae Sputum S. pneumoniae (sputum) Amoxycillin No
14 No C. pneumoniae Serology Haemophilus inﬂuenzae (sputum) Amoxycillin No
15 No C. pneumoniae Serology Ceftriaxone No
16 No Citrobacter freundii Blood culture Amoxycillin No
17 No L. pneumophila Serology Corynebacterium spp.
(blood culture)
Ceftriaxone No
18 No C. pneumoniae Serology Amoxycillin No
19 No Aspergillus spp. Sputum S. pneumoniae (sputum) Ceftriaxone No
20 No C. pneumoniae Serology Ceftriaxone No
21 No L. pneumophila Serology Amoxycillin No
22 No L. pneumophila Serology + UAT S. pneumoniae Penicillin No
23 No M. pneumoniae Serology Amoxycillin No
24 No L. pneumophila Serology S. pneumoniae (blood culture) Amoxycillin No
25 No P. aeruginosa Sputum E. coli (sputum + blood culture) Cefuroxime No
26 No Acinetobacter spp. Sputum Amoxycillin No
27 No M. pneumoniae Serology Cefuroxime No
28 No C. pneumoniae Serology S. pneumoniae (blood culture) Ceftriaxone No
UAT, urinary antigen test.
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sion, this variable was excluded from the ﬁnal
analysis.
Hypoxaemia, acidosis and confusion may all
indicate tissue hypoperfusion caused by oxygen
deﬁciency, and are associated with high mortality
in patients with CAP [30]. As hypoxaemia and
acidosis can be determined only with proper
arterial blood-gas analysis, the importance of
performing this diagnostic procedure at admis-
sion should be emphasised. In contrast to the
Glasgow Coma Score, confusion, deﬁned as an
acute alteration in the mental state of patients, as
observed by family or treating physicians, was an
independent predictor for clinical failure. How-
ever, this deﬁnition does not use an objective
scale, which limits the internal validity of the
model and its applicability in other settings.
Remarkably, a history of chronic heart failure
was related inversely to early clinical failure.
Although it is possible that some patients with a
history of heart failure were admitted because of
congestive heart failure, which is sometimes
difﬁcult to differentiate from pneumonia on a
chest X-ray, all patients had evidence of new or
progressive inﬁltrates on chest X-ray, fulﬁlled the
clinical criteria for pneumonia, and had a PSI
score of >90, or fulﬁlled the ATS criteria for severe
CAP. Although heart failure has been associated
with an adverse clinical outcome in patients with
CAP, it has also been associated with a high risk
for viral pneumonia [31,32]. It is, therefore,
possible that viral respiratory infections with a
less severe course were more prevalent among
patients with heart failure. Indeed, no pathogenic
bacteria were isolated from 68% of patients with
heart failure, compared with 45% of patients
without heart failure (p 0.02).
In univariate analysis, treatment with a combi-
nation of b-lactams and macrolides was associated
with early failure. In The Netherlands, most
patients hospitalised with severe CAP on regular
wards are treated with b-lactam monotherapy,
although combination therapy is sometimes used
for more severe cases of CAP, as judged by the
treating physician. There was no statistically
signiﬁcant difference in the prevalence of inap-
propriate treatment prescribed for failing and
responding patients. An atypical pathogen was
detected in the majority of patients who received
inappropriate treatment and who were not treated
with a macrolide or ﬂuoroquinolone. The most
common pathogens isolated from these patients
were C. pneumoniae and M. pneumoniae, both of
which usually cause mild infections. Moreover,
diagnosis of atypical infections by means of
serological investigations is difﬁcult, especially
for C. pneumoniae, with high rates of false-positives
[33]. The possible inﬂuence of penicillin resistance
in S. pneumoniae on early clinical failure could not
be investigated, as pneumococcal resistance to
penicillins in The Netherlands is <1%.
The present study has a number of limitations.
First, evaluation of patients included in a clinical
trial risks selecting patients who differ from those
encountered in daily clinical practice. However,
analysis of a sample of 56 consecutive patients
meeting the inclusion criteria who were unable or
unwilling to provide informed consent showed a
similar disease severity (average PSI score of
106.45) and age (average age 68.4 years) com-
pared with the study population. Therefore,
generalisation of the results to immunocompetent
patients admitted to non-ICU wards because of
severe CAP seems justiﬁed. Second, while explicit
deﬁnitions of clinical response are absent, criteria
for clinical stability usually include normalisation
of heart rate, systolic blood pressure, respiratory
rate, temperature, oxygenation and mental status
[12,34]. Therefore, these criteria were used to
deﬁne clinical failure, although the use of other
criteria may lead to different outcomes. This is
illustrated by the lower rates of failure in other
studies in which different criteria for early failure
were used, including lack of response or worsen-
ing of clinical and ⁄ or radiological status after
48–72 h, a requirement for changes in therapy,
and ⁄ or performance of invasive procedures for
diagnostic and therapeutic purposes [14,35]. Fur-
thermore, the higher failure rate in the present
study was probably also related to the strict
selection of severe CAP. Third, the deﬁnition used
for severity of disease can be questioned. Severe
CAP was deﬁned on the basis of higher PSI scores
and ATS criteria. In the present cohort, only 19%
of patients were in Fine class V, which probably
explains the relatively low mortality rate in the
study in comparison with the original derivation
cohort. In addition, patients who were admitted
directly to an ICU were not included in the
analysis, which probably inﬂuenced mortality
rates in the cohort when compared with Fine’s
original derivation cohort [16].
In patients who do not respond to initial
therapy, the possibility of an incorrect diagnosis,
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an inadequate host-related response, and drug-
related or pathogen-related problems, e.g., anti-
biotic-resistant pathogens, should be considered.
However, the feature that is most important in
early clinical failure has not yet been determined.
In the present study, strict diagnostic criteria for
CAP were used for inclusion, discordant therapy
appeared not to be associated with early clinical
failure, and all isolates of S. pneumoniae were
susceptible to b-lactam antibiotics. Nevertheless,
31% of patients still fulﬁlled the criteria for early
clinical failure. Therefore, an inadequate host
response was probably the most important factor
in early treatment failure in the study cohort.
Whether genetic predisposition, as suggested
recently [36–38], contributes to early failure
remains to be determined.
In summary, clinical and biochemical data that
are usually assessed routinely in patients with
CAP can be used to indicate the possibility of
early clinical failure in patients hospitalised with
severe CAP. Close monitoring of patients at high
risk for treatment failure may prevent unneces-
sary deaths, ICU admissions and associated costs.
Early identiﬁcation of patients at low risk for early
failure may assist physicians in scheduling treat-
ment strategies, e.g., whether or not to switch to
oral antibiotics early in the treatment programme.
The prognostic variables identiﬁed in the present
study are easy to assess and might be helpful in
reaching these treatment decisions. The PSI score
predicted early clinical failure in multivariate
analysis nearly as accurately as the combination
of the four variables mentioned above. Therefore,
these variables seem to be more practical for daily
use. Nevertheless, the prediction rules derived
from the data require validation in external
cohorts of severe CAP to evaluate their general
applicability.
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